BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
– Updated data presented at ISSCR 2025 demonstrates >50% improvement in pain and function in a significant portion of cLDD subjects –
– Number of evaluated subjects increases by more than two-fold since last update ––
MELVILLE, N.Y., June 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ('BioRestorative,' 'BRTX' or the 'Company') (NASDAQ: BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today announced the presentation of promising preliminary blinded data from the first 36 subjects in its ongoing Phase 2 clinical trial of BRTX-100, an autologous stem cell therapy for chronic lumbar disc disease (cLDD). This data was shared at the prestigious ISSCR 2025 Annual Meeting in Hong Kong by Francisco Silva, Vice President of Research and Development.
The U.S. Food and Drug Administration ('FDA') is requiring at least a greater than 30% improvement in function in the Oswestry Disability Index ('ODI') and a greater than 30% reduction in pain on the Visual Analog Scale ('VAS') in determining whether the clinical trial will be allowed to proceed and ultimately gain Biologics License Application (BLA) approval.
Key Highlights:
Patient Numbers Growing: The number of subjects evaluated has increased from 15 to 36 since the Company's last press release — an important milestone toward full Phase 2 enrollment (up to 99 subjects).
Compelling Clinical Signals:
Over 74% of subjects showed >50% improvement in function (ODI) by 52 weeks;
Over 72% of subjects reported >50% reduction in pain (VAS) by 52 weeks;
Combined >50% improvement in both ODI and VAS measures was achieved by a meaningful portion of subjects across all timepoints.
Excellent Safety Profile: No serious adverse events (SAEs) or dose-limiting toxicities reported between 26 and 104 weeks at the target dose (40 million cells).
Strengthening Data: Each new data analysis has outperformed prior releases, highlighting an upward trend in efficacy markers.
The following is a detailed breakdown of the subjects that had greater than 50% improvement in function, as measured by ODI, greater than 50% decrease in pain, as measured by VAS, and greater than 50% improvement in both ODI and VAS:
Week
Percentage of Subjects With >50% Average Improvement in ODI
Percentage of Subjects With >50% Average Improvement in VAS
Number of Subjects With >50% Average Improvement in Both ODI and VAS
Baseline
0.00
%
0.00
%
0/36
12
67.57
%
73.82
%
5/25
26
74.04
%
76.94
%
6/15
52
74.63
%
72.35
%
8/10
104
75.13
%
68.54
%
2/4
'With every new analysis, our confidence grows that BRTX-100 is positioned to meet and potentially exceed the FDA's functional and pain reduction thresholds,' said Lance Alstodt, Chief Executive Officer of BioRestorative. 'We are excited by the trajectory of this material milestone and its potential to address a massive unmet need in chronic lower back pain — one of the largest global healthcare burdens. We believe this data moves us one step closer to bringing a much-needed, non-surgical therapeutic option to market and should add to further value enhancing inflection points in the near-term.'
The data were presented as part of the Clinical Innovations track at ISSCR 2025, an event that attracts the world's top stem cell and regenerative medicine researchers, clinicians, and investors.
About the BRTX-100 Phase 2 Trial
BRTX-100 is a novel, autologous cell-based therapy designed to treat patients suffering from painful lumbosacral disc degeneration. The Phase 2 trial is a randomized, double-blinded, placebo-controlled study that will enroll up to 99 subjects at 16 leading U.S. sites. Subjects are randomized 2:1 to receive either BRTX-100 or placebo via a minimally invasive outpatient procedure.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration ('FDA') Investigational New Drug ('IND') clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells ('BADSC') to generate brown adipose tissue ('BAT'), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen KilmerInvestor RelationsDirect: (646) 274-3580 Email: skilmer@biorestorative.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
14 minutes ago
- Time Magazine
FDA Warns Public Not to Eat Potentially Radioactive Shrimp
The Food and Drug Administration has warned the public not to consume certain frozen shrimp products sold at Walmart due to possible contamination with Cesium-137, a radioactive isotope. It said the warning affects the Great Value brand of raw frozen shrimp sold at the superstore, adding that anyone who purchased the product should dispose of it. A statement from the agency said the FDA was 'actively investigating reports of Cesium-137 (Cs-137) contamination in shipping containers and frozen shrimp products' in a shipment from Indonesia. It said that the U.S. Customs & Border Protection (CBP) had detected Cs-137 in shipping containers at four U.S. ports: Los Angeles, Houston, Savannah, and Miami. The FDA added that although it had not confirmed the presence of contamination in any commercial product in the United States, the shrimp products appear 'to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern.' 'If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away. Do not eat or serve this product,' the FDA statement added. The FDA said limited exposure to Cs-137 can cause 'an elevated risk of cancer, resulting from damage to DNA within living cells of the body.' The FDA has recommended that Walmart recall this product. TIME has contacted Walmart for a response. This is a developing story.
Forbes
14 minutes ago
- Forbes
FDA Suggest Walmart Recalls Frozen Shrimp After Radiation Detected At Port
The Food and Drug Administration is warning that some Great Value brand frozen shrimp sold at Walmart could be contaminated with radioactive isotope Cesium-137 after Customs and Border Protection detected the substance in shipping containers at four major American ports and at least one sample of shrimp. Cesium-137 was detected in some frozen shrimp coming from Indonesia—but none that have been sold in stores yet. getty The FDA is investigating the potential contamination and has not 'confirmed the presence of contamination in any product in commerce,' they are still warning consumers to avoid eating shrimp that come from the same Indonesian producer BMS Foods. The FDA is recommending Walmart recall frozen shrimp coming from BMS Foods, and the retailer has not returned a request for comment from Forbes. This is a breaking story and will be updated.
CBS News
14 minutes ago
- CBS News
Walmart's Great Value shrimp has risk of radioactive contamination, FDA says
Some frozen shrimp sold at Walmart under the Great Value label are at risk of radioactive contamination and shouldn't be consumed, according to a warning from the U.S. Food and Drug Administration. The frozen shrimp were imported from Indonesian company PT. Bahari Makmur Sejati and sold at Walmart stores as Great Value brand frozen raw shrimp, the FDA said on Tuesday. The agency noted it has recommended that Walmart recall the product. Walmart didn't immediately respond to a request for comment. The shrimp could be contaminated with a radioactive isotope called Cesium-137, although the FDA said that no products as of yet have tested positive for it. The agency said it issued the warning about Walmart's Great Value shrimp after it had detected Cesium-137 in a single shipment of frozen shrimp from PT. Bahari Makmur Sejati. That shipment "did not enter U.S. commerce," the FDA said. Here's what to know about the warning. The FDA said that consumers "should not eat or serve certain lots of Great Value raw frozen shrimp from Walmart." The lots are: Consumers who bought the shrimp cited in the FDA's notice should throw it away, the agency said. "Distributors and retailers should dispose of this product and should not sell or serve this product," the FDA added. Cesium-137, or Cs-137, is the radioactive form of the element cesium, according to the U.S. Environmental Protection Agency. Produced by nuclear fission, it's used in medical devices and is also a byproduct of nuclear fission in nuclear reactors and weapons testing, the EPA notes. The Cesium-137 detected in the imported shrimp was about 68 Bq/kg, which the FDA said sits below its threshold of 1200 Bq/kg for "levels of concern" for imported foods. "At this level, the product would not pose an acute hazard to consumers," the FDA said in its warning notice. However, the FDA noted that repeated low-dose exposure to Cesium-137 carries an "elevated risk of cancer, resulting from damage to DNA within living cells of the body." It added, "Avoiding products like the shipment FDA tested with similar levels of Cs-137 is a measure intended to reduce exposure to low-level radiation that could have health impacts with continued exposure over a long period of time."
